ClinConnect ClinConnect Logo
Search / Trial NCT06700564

The Diagnostic Efficacy and Lesion Detection Advantages of 18F-FDG PET/CT and Enhanced MRI in Hepatic Malignancies

Launched by SHANGHAI EAST HOSPITAL · Nov 19, 2024

Trial Information

Current as of June 26, 2025

Not yet recruiting

Keywords

Hepatoma Pet/Mr Contrast Enhanced Mr

ClinConnect Summary

This clinical trial is studying a new imaging technique called 18F-FDG PET/MR to see how well it can detect liver tumors and other liver lesions, especially in patients suspected of having liver cancer or metastases. Currently, traditional imaging methods like ultrasound and CT scans have limitations in accurately identifying the nature of liver lesions, which is crucial for proper treatment. The researchers want to find out if the combination of PET and MRI can provide clearer and more accurate results, potentially leading to better treatment outcomes for patients.

To participate in this trial, individuals must be at least 18 years old and have findings from previous imaging that suggest they might have liver lesions. They should also be able to undergo the PET/MR examination and agree to follow the study procedures. However, those with certain health conditions, pregnant or breastfeeding women, and people with allergies to MRI contrast agents will not be eligible. Participants can expect to undergo advanced imaging tests that could help improve how liver diseases are diagnosed and treated in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age ≥ 18 years old; Preliminary findings from other routine imaging examinations;
  • 2. Patients suspected of having liver metastasis or liver lesions, based on clinical symptoms and laboratory tests (such as alpha-fetoprotein levels);
  • 3. Preliminary findings from other routine imaging examinations;
  • 4. Able to perform 18F-FDG PET/MR examination and agree to follow the research procedure.
  • Exclusion Criteria:
  • 1. Patients with a history of allergy to MR contrast agents;
  • 2. Pregnant or lactating women;
  • 3. Patients with severe heart disease, renal failure, liver failure, etc;
  • 4. Patients who are unable to cooperate in completing PET/MR examinations.

About Shanghai East Hospital

Shanghai East Hospital, affiliated with Tongji University, is a leading healthcare institution in China dedicated to providing high-quality medical services, education, and research. Renowned for its advanced clinical practices and cutting-edge technologies, the hospital plays a pivotal role in the advancement of medical science through innovative research and clinical trials. Committed to improving patient outcomes, Shanghai East Hospital collaborates with various stakeholders to explore new therapies and treatment modalities, enhancing the collective understanding of health and disease. Their clinical trial initiatives focus on addressing pressing medical needs while ensuring the highest ethical standards and patient safety.

Locations

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported